Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review Review
| Authors: | Deipolyi, A. R.; Ward, R. C.; Riaz, A.; Vogl, T.; Simmons, R. M.; Pieper, C. C.; Bryce, Y. |
| Review Title: | Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review |
| Abstract: | Minimally invasive locoregional therapies have a growing role in the multidisciplinary treatment of primary and metastatic breast cancer. Factors contributing to the expanding role of ablation for primary breast cancer include earlier diagnosis, when tumors are small, and increased longevity of patients whose condition precludes surgery. Cryoablation has emerged as the leading ablative modality for primary breast cancer owing to its wide availability, the lack of need for sedation, and the ability to monitor the ablation zone. Emerging evidence suggests that in patients with oligometastatic breast cancer, use of locoregional therapies to eradicate all disease sites may confer a survival advantage. Evidence also suggests that transarterial therapies - including chemoembolization, chemoperfusion, and radioembolization - may be helpful to some patients with advanced liver metastases from breast cancer, such as those with hepatic oligoprogression or those who cannot tolerate systemic therapy. However, the optimal modalities for treatment of oligometastatic and advanced metastatic disease remain unknown. Finally, locoregional therapies may produce tumor antigens that in combination with immunotherapy drive antitumor immunity. Although key trials are ongoing, additional prospective studies are needed to establish the inclusion of interventional oncology in societal breast cancer guidelines to support further clinical adoption and improved patient outcomes. © American Roentgen Ray Society. |
| Keywords: | cancer survival; treatment outcome; overall survival; review; cancer recurrence; cisplatin; doxorubicin; chemoembolization; patient selection; liver neoplasms; bone metastasis; adjuvant therapy; cancer radiotherapy; antineoplastic agent; cancer palliative therapy; ipilimumab; cancer immunotherapy; quality of life; breast cancer; tumor volume; sedation; patient monitoring; practice guideline; breast neoplasms; tumor antigen; cancer research; length of stay; liver metastasis; lung metastasis; early diagnosis; breast tumor; liver tumor; high intensity focused ultrasound; brachytherapy; intermethod comparison; tumor immunity; liver disease; longevity; mitomycin; cryoablation; radiofrequency ablation; metastatic breast cancer; embolization, therapeutic; partial hepatectomy; catheter ablation; medical expert; axillary lymph node dissection; narrative; minimally invasive procedure; laser thermotherapy; microwave ablation; eradication therapy; yttrium 90; radioembolization; locoregional therapy; immune checkpoint inhibitor; cancer prognosis; nivolumab; humans; human; female; starch microsphere; artificial embolization; microwave thermotherapy; oligometastatic disease; embocept; pharmacept |
| Journal Title: | American Journal of Roentgenology |
| Volume: | 222 |
| Issue: | 2 |
| ISSN: | 0361-803X |
| Publisher: | American Roentgen Ray Society |
| Date Published: | 2024-02-01 |
| Start Page: | e2329454 |
| Language: | English |
| DOI: | 10.2214/ajr.23.29454 |
| PUBMED: | 37377360 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
